Andrew Dunn is a senior biopharma correspondent at Endpoints News, specializing in drug development and life sciences. With prior roles at Business Insider and BioPharmaDive, he brings extensive expertise in biopharma journalism. Based in New York, he covers major industry developments including AI-driven R&D innovations and leadership shifts in pharmaceutical companies.

‌